Ankilozan spondilitli hastalarda güncel tedavi yaklaşımları

Ankilozan spondilit (AS) başlıca sakroiliak eklemler ve omurgayı etkileyen kronik, infamatuar bir romatizmal hastalık olarak, daha çok erkeklerde sıklıkla 2. ve 3. On yılda ortaya çıkan bir hastalıktır. ASli hastalarda tedavinin temelini ağrı ve infamasyonu azaltan nonsteroid anti-inflamatuar ilaçlar (NSAİİ) almaktadır. Modifiye edici antiromatizmal (DMARD) ilaçlar, AS hastalığın tedavisinde etkinliği kanıtlanamamıştır. DMARDların kullanımı semptomların iyileştirilmesinde yeterli bulunmamıştır. Son zamanlarda anti tümör nekrozis faktör (TNF) blokerleri olan Golimumab, Etanersept, Adalimumab, İnfiksimab gibi ajanlar AS tedavisinde umut verici sonuçlar vermektedir. TNF blokerleri AS hastalarının fiziksel işlevlerinde, yaşam kalitesinde ve semptomlarında iyileşme sağlamaktadır. Bu yazı ASli hastaların güncel farmakolojik tedavisi üzerine odaklanmıştır.

Current treatment approaches in patients with ankylosing spondylitis

Ankylosing spondylitis (AS) is a chronic, infammatory, rheumatic disease that mainly affects sacroiliac joints and spine. AS predominantly occurs more often in males and typically begins in the second or third decade. The mainstay of therapy in AS are nonsteroidal anti-infammatory drugs, which reduce infammation and pain. Disease modifying antirheumatic drugs (DMARD) did not have enough evidence to prove their effect in AS treatment. The use of DMARD may not suffcient to improve the treatment and symptoms. Currently, TNF-blockers such as, Golimumab Etanersept Adalimumab İnfiksimab have promising results in the treatment of AS. TNF-blockers mprove the clinical signs and symptoms, and improve the patients physical function and quality of life. This manuscript is focused that Current pharmacological treatments İn patients with ankylosing spondylitis.

PDF

___

1. van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am 1998;24:663- 676, vii.
2. Weisman MH RJ, Heijde D. Ankilozan Spondilit ve Spondiloar- tropatiler. Ankara: Veri Medikal Yayıncılık; 2008.
3. Dougados M, Dijkmans B, Khan M, et al. Conventional treatments for ankylosing spondylitis. Annals of the rheumatic diseases 2002, 61 Suppl 3:iii 40-50.
4. Lavie F, Pavy S, Dernis E, et al. Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of rec - ommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:346-352.
5. Kwan D, William R. Bartle, and Scott E. Walker. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999;9: 68-75.
6. Şahin E. Farmakolojik ajanlar. Fiziksel Tıp ve Rehabilitasyon Pratik El Kitabı. Tan CJ, editör. Şendur ÖF, Çeviri ed. 2.baskı İstanbul: Güneş Tıp Kitabevleri;2008. p.333-357.
7. Melli M, Kayaalp SO. Non-Steroidal antiinfamatuar ilaçlar. Kayaalp SO (Editör). Rasyonel Tedavi Yönünden Tibbi Farmakoloji 11. Baskı. Ankara: Hacettepe-Taş;2005 p.837-870.
8. Maugars Y, Mathis C, Berthelot JM, et al: Assessment of the effcacy of sacroiliac corticosteroid injections in spon - dylarthropathies: a double-blind study. Brit J Rheumatol 1996;35:767-770.
9. van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylos - ing spondylitis with non-pharmacological treatment and non- biologic drugs: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spon - dylitis. Rheumatology 2012;51:1388-1396.
10. Braun J, Pham T, Sieper J, et al: International ASAS consen - sus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-824.
11. Ozgocmen S, Akgul O, Altay Z, et al: Expert opinion and key recommendations for the physical therapy and rehabilitation of patients with ankylosing spondylitis. Int J Rheum Dis 2012;15:229-238.
12. Brooks P. Slow acting anti rheumatic drugs and cytotoxic agents. In: Schumacher HR, ed. Primer on the Rheumatic Diseases. Atlanta: Arthritis Foundation; 1993. p303-6
13. Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis: a sys - tematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-432.
14. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a ma- jor clinical response (BASDAI 50) to tumour necrosis fac - tor α blockers in ankylosing spondylitis. Ann Rheum Dis, 2004;63:665-670.
15. Braun J. V, Van Den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum dis 2011;70: 896-904.
16. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the rheumatic diseases 2011;70:905-908.
17. van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infix - imab Therapy Study G: Effcacy and safety of infiximab in patients with ankylosing spondylitis: results of a random - ized, placebo-controlled trial (ASSERT). Arthrit Rheum 2005;52:582-591.
18. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infiximab: a randomised controlled multicentre trial. The Lancet 2002;359:1187-1193.
19. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthrit Rheum 2003; 48:3230-3236.
20. Inman RD, Davis JC Jr, Heijde D, et al. Effcacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthrit Rheum 2008; 58:3402-3412.
21. Braun J, Davis J, Dougados M, et al. First update of the inter- national ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:316-320.
23. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthrit Care Res 2008;59:762-784.
24. Black R A, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-R from cells. Nature 1997;385:729-733.
25. Pay S. Romatizmal Hastalıklarda Anti-TNF İlaç Kullanımı. Turkiye Klinikleri J Med Sci, 2006;26:430-440.
26. Gorman JD, Sack, K E, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-1356.
27. Dvis JC, Webb A, Lund S, Sack K, Result from an open-label extension study of etanercept in ankylosing spondylitis. Art Rheum 2004;51:302-104
28. Brandt J, Listing J, Haibel H, et al. Long-term effcacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheum 2005;44:342-348.
29. Den Broeder AA, Saxne T, Heinegård D, et al. Long term anti- tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002; 61:311-318.
30. U.S Food and Drug administration, Full prescribing informa- tion, Adaliumab.2008. Available at:www.fda.gov.
31. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279.
32. Callhoff J, Sieper J, Weiß A, et al. Effcacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis doi:10.1136/ 2014-205322 [Epub ahead of print]
33. Patel Aarat M, and Larry W. Moreland. Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Ann Rheum Dis 2010;6: 855-866.
34. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Infamm Bowel Dis 2007;13:1323-1332.
35. Evans Ashley T, Lee SD. A review and expert opinion of the use of certolizumab for Crohns disease. Expert Opin Biol Ther 2012; 12:363-370.
36. Landewé R, Braun, J, Deodhar A, et al . Effcacy of certoli- zumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a dou - ble-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2013;73:39-47.
37. Dhillon S: Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs 2014;74:999-1016.
38. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-320.
39. Davis JC. Ankylosing Spondylitis In: Koopman WJ, Moreland LW (eds). Arthritis and Allied Conditions. A Textbook of Rheumatology Lippincott Williams and Wilkins P. 2005 p.1319-1333.
40. Braun Jv, Van Den Berg R, Baraliakos X, et al. : 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.